ArticleBMC complementary medicine and therapies2025
Exploration of the potential mechanism of cyclolinopeptides-mediated antiosteoporosis effects via network pharmacology analysis.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A double-network fish gelatin/sodium alginate composite hydrogel as a carrier for the sustained release of a soy-derived osteogenic peptide.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOsteoporosis poses a significant global health burden. Cyclolinopeptides (CLPs), cyclic hydrophobic peptides derived from flaxseed oil, exhibit antiosteoporotic, antioxidant, and immunomodulatory properties, but their therapeutic potential for osteoporosis remains underexplored. This study was aimed to investigate the potential protective effects of CLP-A, CLP-E, and CLP-P on the treatment of osteoporosis in vitro.
methodsNetwork pharmacology identified overlapping targets of CLP-A/E/P and osteoporosis (sourced from GeneCards, DrugBank, DisGeNET, PharmMapper, and BindingDB). Core targets were prioritized via PPI network analysis (Cytoscape). In vitro assays were used to assess CLP cytotoxicity (CCK-8 on MC3T3-E1 and RAW264.7 cells), osteogenic differentiation (alizarin red S staining), and alkaline phosphatase (ALP) activity.
resultsNetwork pharmacology analysis revealed that the compounds CLP-A/ E/P were involved in the regulation of diverse biological functions associated with osteoporosis, including signal transduction and positive regulation of transcription from the RNA polymerase II promoter. These signaling pathways are involved primarily in the pathways related to cancer, the PI3K-Akt signaling pathway and the Ras signaling pathway. The experimental results demonstrated that CLP-A/ E/P had no direct toxic effects on MC3T3-E1 Cells or RAW264.7 Cells for 24-48 h, respectively. CLP-A/E/P were shown to enhance MC3T3-E1 Cell osteogenesis and ALP activity.
conclusionsThis study demonstrated that CLP-A, CLP-E, and CLP-P enhance osteogenesis and ALP activity in MC3T3-E1 cells without causing cytotoxicity, suggesting their potential as therapeutic agents for osteoporosis. Network pharmacology further highlights their involvement in key signaling pathways, such as the PI3K-Akt and Ras signaling pathways, which are critical in bone metabolism and osteoporosis, however, further investigation is needed to elucidate the underlying mechanism involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.